

# PRECEPTORSHIP PROGRAMME

## Immuno-Oncology

From the essentials of tumour  
immunology to clinical application

**ESMO VIRTUAL  
PRECEPTORSHIP**

**22-23 NOVEMBER 2021**

**Co-Chairs**

Victoria G. Atkinson, Australia

Andrew Furness, United Kingdom

# ESMO VIRTUAL PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY

From the essentials of tumour immunology to clinical application

**22-23 November 2021**

---

## CO-CHAIRS:

Victoria G. Atkinson, Australia  
Andrew Furness, United Kingdom

## SPEAKERS:

Stephen Chan, Hong Kong	Kenneth J. O'Byrne, Australia
Eva Comperat, France	Solange Peters, Switzerland
Boon-Cher Goh, Singapore	James Reading, United Kingdom
Ravindran Kanesvaran, Singapore	Kohei Shitara, Japan
Soo Chin Lee, Singapore	Ines Pires da Silva, Australia
Ignacio Melero Bermejo, Spain	Wan Zamariah B. Wan Ishak, Malaysia
Tony S. K. Mok, Hong Kong	

---

## LEARNING OBJECTIVES

- To understand the basics of tumour immunology
- To learn about the essentials of immunotherapies and their present indication in cancer treatment
- To learn about the status of development and clinical experience of immunotherapy in different tumour types

---

## ACCREDITATION

The programme of this event has been accredited with **7 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to [esmo.org](http://esmo.org).

---

## ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



---

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4  
6900 Lugano  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



All timings are to be considered GMT+8 (Singapore Local Time)

## Monday, 22 November 2021

15:00-15:05 5'	<b>Welcome</b>	<b>Victoria G. Atkinson, AU Andrew Furness, UK</b>
15:05-15:45 40'	<b>SESSION 1 Introduction</b>	<b>Chair/Moderator:</b>
15'	Principles of tumour immunology: Explaining cellular immunity and immune surveillance	James Reading, UK
15'	Principles of cancer immunotherapy	Ignacio Melero Bermejo, ES
10'	Discussion	Faculty
15:45-16:55 70'	<b>SESSION 2 Clinical issues</b>	<b>Chair/Moderator:</b>
15'	Predictive biomarkers and response	Kenneth J. O'Byrne, AU
15'	Clinical translation and radiological assessment of efficacy	Boon-Cher Goh, SG
15'	Immune related toxicities and management	Ines Pires da Silva, AU
15'	Balancing costs and clinical benefit in medical oncology	Solange Peters, CH
10'	Discussion	Faculty
16:55-17:05	<b>Break</b>	
17:05-18:00 55'	<b>SESSION 3 Recent advances with ICPI: Results in approved/unapproved indication – part 1</b>	<b>Chair/Moderator:</b>
15'	Non-Small-Cell Lung Cancer	Tony S. K. Mok, HK
15'	Upper GI and colorectal	Kohei Shitara, JP
15'	Hepatocellular carcinoma (HCC)	Stephen Chan, HK
10'	Discussion	Faculty
18:00-18:40 40'	<b>SESSION 4 Audience cases</b>	<b>Chair/Moderator: Victoria G. Atkinson, AU Andrew Furness, UK</b>
40'	Participants clinical case discussion (4x10')	Faculty

## Tuesday, 23 November 2021

15:00-15:55 55'	<b>SESSION 5 Recent advances with ICPI: Results in approved/unapproved indication – part 2</b>	<b>Chair/Moderator:</b>
15'	Head and neck cancer	Wan Zamariah B. Wan Ishak, MY
15'	Gynaecological malignancies and breast cancer	Soo Chin Lee, SG
15'	Melanoma advanced and adjuvant	Victoria G. Atkinson, AU
10'	Discussion	Faculty

<b>15:55-16:20</b> 25'	<b>SESSION 6</b> <b>Recent advances with ICPI: Results in approved/unapproved indication – part 3</b>	<b>Chair/Moderator:</b>
15'	Advanced urinary cancer (renal and bladder)	Eva Comperat, FR
10'	Discussion	Faculty
<b>16:20-16:30</b>	<b>Break</b>	
<b>16:30-17:40</b> 70'	<b>SESSION 7</b> <b>Audience cases</b>	<b>Chair/Moderator:</b> <b>Victoria G. Atkinson, AU</b> <b>Andrew Furness, UK</b>
70'	Participants clinical case discussion (7x10')	Faculty
<b>17:40-18:20</b> 40'	<b>SESSION 8</b> <b>Future of immuno-oncology</b>	<b>Chair/Moderator:</b>
15'	Cell-based therapy/Cellular therapy	Andrew Furness, UK
15'	Combination therapy: future directions	Ravindran Kanesvaran, SG
10'	Discussion	Faculty
<b>18:20-18:25</b> 5'	<b>Closure and farewell</b>	<b>Victoria G. Atkinson, AU</b> <b>Andrew Furness, UK</b>

**Note:** Each 10-minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion